Phathom Pharmaceuticals
PHAT
84 hedge funds and large institutions have $919M invested in Phathom Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 12 closing their positions.
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
13% more capital invested
Capital invested by funds: $815M → $919M (+$104M)
11% more funds holding
Funds holding: 76 → 84 (+8)
0.19% less ownership
Funds ownership: 78.58% → 78.4% (-0.19%)
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$34.2M |
| 2 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$8.35M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$8.12M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.41M |
| 5 |
Two Sigma Investments
New York
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$29.7M |
| 2 |
JG
Jefferies Group
New York
|
-$8.22M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$5.07M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$5.01M |
| 5 |
LM
Luminus Management
Houston,
Texas
|
-$4.22M |
PHAT Hedge Fund Activity: Q1 2021 in Review
84 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q1 2021, worth a combined $919M — up 13% from $815M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PHAT positions and 12 closed out — a net gain of 8 holders — while 22 added to existing stakes and 23 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, opening a new position worth an estimated $34.2M. The largest seller was RA Capital Management, cutting an estimated $29.7M.
- 84 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q1 2021, up from 76 in Q4 2020.
- Funds reported $919M of Phathom Pharmaceuticals stock for Q1 2021, up 13% quarter-over-quarter.
- 20 funds opened new Phathom Pharmaceuticals positions in Q1 2021 and 12 closed out, a net change of +8 holders.
- The largest Phathom Pharmaceuticals buyer in Q1 2021 was Gilder Gagnon Howe & Co, an estimated $34.2M added.
- The largest Phathom Pharmaceuticals seller in Q1 2021 was RA Capital Management, an estimated $29.7M sold.
Based on aggregated 13F filings for Q1 2021.